Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3
27 July 2023 - 9:00PM
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage
biopharmaceutical company advancing targeted protein degradation to
deliver novel small molecule protein degrader medicines, will
report second quarter 2023 financial results on August 3, 2023, and
will host a conference call at 8:30 a.m. ET that day.
To access the August 3 conference call via phone,
please dial +1 (800) 715-9871 (US) or +1 (646) 307-1963
(International) and ask to join the Kymera Therapeutics call or
provide Conference ID 7353312. A live webcast of the Company’s
conference call will be available under the “Events and
Presentations” section of the Investors page on the Company’s
website at www.kymeratx.com.
About Kymera Therapeutics
Kymera is a biopharmaceutical company pioneering
the field of targeted protein degradation, a transformative
approach to address disease targets and pathways inaccessible with
conventional therapeutics. Kymera’s Pegasus platform is a powerful
drug discovery engine, advancing novel small molecule programs
designed to harness the body’s innate protein recycling machinery
to degrade dysregulated, disease-causing proteins. With a focus on
undrugged nodes in validated pathways, Kymera is advancing a
pipeline of novel therapeutic candidates designed to address the
most promising targets and provide patients with more effective
treatments. Kymera’s initial programs target IRAK4, IRAKIMiD, and
STAT3 within the IL-1R/TLR or JAK/STAT pathways, and the MDM2
oncoprotein, providing the opportunity to treat patients with a
broad range of immune-inflammatory diseases, hematologic
malignancies, and solid tumors.
Founded in 2016, Kymera is headquartered in
Watertown, Mass. Kymera has been named a “Fierce 15” company by
Fierce Biotech and has been recognized by both the Boston Globe and
the Boston Business Journal as one of Boston’s top workplaces. For
more information about our people, science, and pipeline, please
visit www.kymeratx.com or follow us on Twitter or LinkedIn.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including, without limitation,
implied and express statements by Kymera Therapeutics regarding
its: strategy, business plans and objectives for the IRAK4,
IRAKIMiD, STAT3, and MDM2 degrader programs; plans and timelines
for the preclinical and clinical development of its product
candidates, including the therapeutic potential, clinical benefits
and safety thereof; expectations regarding timing, success and data
announcements of current ongoing preclinical and clinical trials.
The words "may," "might," "will," "could," "would," "should,"
"expect," "plan," "anticipate," "intend," "believe," "expect,"
"estimate," "seek," "predict," "future," "project," "potential,"
"continue," "target" and similar words or expressions are intended
to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, risks associated
with: the impact of COVID-19 on countries or regions in which we
have operations or do business, as well as on the timing and
anticipated results of our current and future preclinical studies
and clinical trials, supply chain, strategy and future operations;
the delay of any current and future preclinical studies or clinical
trials or the development of Kymera Therapeutics' drug candidates;
the risk that the results of current preclinical studies and
clinical trials may not be predictive of future results in
connection with current or future preclinical and clinical trials,
including those for KT-474, KT-333, KT-413 and KT-253; Kymera
Therapeutics' ability to successfully demonstrate the safety and
efficacy of its drug candidates; the timing and outcome of the
Kymera Therapeutics' planned interactions with regulatory
authorities; obtaining, maintaining and protecting its intellectual
property; and Kymera Therapeutics' relationships with its existing
and future collaboration partners. These and other risks and
uncertainties are described in greater detail in the section
entitled "Risk Factors" in the Quarterly Report on Form 10-Q for
the quarter ended March 31, 2023 filed on May 4, 2023, as well as
discussions of potential risks, uncertainties, and other important
factors in Kymera Therapeutics' subsequent filings with the
Securities and Exchange Commission. In addition, any
forward-looking statements represent Kymera Therapeutics' views
only as of today and should not be relied upon as representing its
views as of any subsequent date. Kymera Therapeutics explicitly
disclaims any obligation to update any forward-looking statements.
No representations or warranties (expressed or implied) are made
about the accuracy of any such forward-looking statements.
Investor Contact: |
|
Media
Contact: |
|
|
|
Bruce Jacobs |
|
Todd Cooper |
Chief Financial Officer |
|
Senior Vice President, Corporate Affairs |
investors@kymeratx.com |
|
media@kymeratx.com |
857-285-5300 |
|
857-285-5300 |
|
|
|
Chris Brinzey |
|
|
Managing Director, Westwicke |
|
|
chris.brinzey@westwicke.com |
|
|
339-970-2843 |
|
|
Kymera Therapeutics (NASDAQ:KYMR)
Historical Stock Chart
From Apr 2024 to May 2024
Kymera Therapeutics (NASDAQ:KYMR)
Historical Stock Chart
From May 2023 to May 2024